ONCOCROSS

  • Company

    • Mission

    • About Us

    • History

    • Leadership

    • Scientific Advisory Board

  • Business Areas

    • Neo Omics

    • DBB

    • Early Cancer Detection & Monitoring

    • Collaboration

  • Technology Platform

    • RAPTOR AI® VERSION 2.0

    • ONCOfind AI ®

  • Pipeline

  • News/IR

    • Notice

    • Press Releases

    • IR Materials

    • Knowledge Hub

    • Latest Cancer Information

    • Disclosure Information

    • Stock Information

  • OncoMaster

CONTACT US
  • KR
  • EN
  • Company

    • Mission

    • About Us

    • History

    • Leadership

    • Scientific Advisory Board

  • Business Areas

    • Neo Omics

    • DBB

    • Early Cancer Detection & Monitoring

    • Collaboration

  • Technology Platform

    • RAPTOR AI® VERSION 2.0

    • ONCOfind AI ®

  • Pipeline

  • News/IR

    • Notice

    • Press Releases

    • IR Materials

    • Knowledge Hub

    • Latest Cancer Information

    • Disclosure Information

    • Stock Information

  • OncoMaster

  • KR
  • EN
CONTACT US
  • Main
  • News/IR
  • Disclosure Information

Disclosure Information

35 Posts
  • Report on Major Issues(Decision on Merger)

    04-15-2026
  • Report on the Grant of Stock Options

    04-09-2026
  • Outcomes of Annual Meeting of Shareholders

    03-27-2026
  • Report on the Grant of Stock Options

    03-27-2026
  • Report on the Appointment, Dismissal or Early Retirement of Outside Directors

    03-27-2026
  • Submission of Audit Report

    03-19-2026
  • Annual Report

    03-19-2026
  • Resolutions for Convocation of General Meeting of Shareholders

    03-05-2026
  • Reporting reasons for holding general shareholders' meeting on the most concentrated date

    03-05-2026
  • Reference Documents for Proxy Solicitation

    03-05-2026
  • Announcement of Convocation of General Meeting of Shareholders

    03-05-2026
  • 30% or More Change in Sales or Profit/Loss(15% or more in the case of large-scale corporations)

    02-10-2026
  • 1
  • 2
  • 3

Please enter a prompt

ONCOCROSS
CEO
Yi Rang KIM / Jihoon KANG
Address
Room 905, 7 Beobwon-ro 11-gil, Songpa-gu, Seoul, Korea (Munjeong-dong, Munjeong Hyundai Knowledge Industry Center 1-2)
Tel
02-717-9967
Fax
02-867-9968
Email
oncocross@oncocross.com
Terms & Conditions Privacy Policy Cookie Policy
ⓒ ONCOCROSS CO., LTD. All Rights Reserved.